Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse

Cancer Genetics and Cytogenetics

Volumn 202, Issue 2, 2010, Pages 101-107

  Wang, Eunice S ^a   Sait, Sheila N J ^a   Gold, David ^a,b   Mashtare, Terry ^a,b   Starostik, Petr ^a   Ford, Laurie Ann ^a   Wetzler, Meir ^a   Nowak, Norma J ^a   Deeb, George ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; NUCLEOPHOSMIN; NUCLEAR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CELL CLONE; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENOMICS; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; KARYOTYPE; LEUKEMIA CELL; LEUKEMIA RELAPSE; LEUKEMOGENESIS; MALE; PRIORITY JOURNAL; CHROMOSOME ABERRATION; ENZYMOLOGY; GENETICS; KARYOTYPING; MIDDLE AGED; NUCLEOTIDE SEQUENCE; RECURRENT DISEASE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA MUTATIONAL ANALYSIS; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENOMICS; HUMANS; IMMUNOPHENOTYPING; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NUCLEAR PROTEINS; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77957078727     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2010.07.117     Document Type: Article

References (43)

1. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92:2322-2333.
2. Byrd J.C., Mrozek K., Dodge R.K., Carroll A.J., Edwards C.G., Arthur D.C., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325-4336.
3. Breems D.A., Van Putten W.L., Huijgens P.C., Ossenkoppele G.J., Verhoef G.E., Verdonck L.F., et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005, 23:1969-1978.
4. Kern W., Haferlach T., Schnittger S., Ludwig W.D., Hiddemann W., Schoch C. Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy. Leukemia 2002, 16:2084-2091.
5. Testa J.R., Mintz U., Rowley J.D., Vardiman J.W., Golomb H.M. Evolution of karyotypes in acute nonlymphocytic leukemia. Cancer Res 1979, 39:3619-3627.
6. Estey E., Keating M.J., Pierce S., Stass S. Change in karyotype between diagnosis and first relapse in acute myelogenous leukemia. Leukemia 1995, 9:972-976.
7. Garson O.M., Hagemeijer A., Sakurai M., Reeves B.R., Swansbury G.J., Williams G.J., et al. Cytogenetic studies of 103 patients with acute myelogenous leukemia in relapse. Cancer Genet Cytogenet 1989, 40:187-202.
8. Mullighan C.G., Phillips L.A., Su X., Ma J., Miller C.B., Shurtleff S.A., et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008, 322:1377-1380.
9. Tyybakinoja A., Elonen E., Piippo K., Porkka K., Knuutila S. Oligonucleotide array-CGH reveals cryptic gene copy number alterations in karyotypically normal acute myeloid leukemia. Leukemia 2007, 21:571-574.
10. Suela J., Alvarez S., Cigudosa J.C. DNA profiling by arrayCGH in acute myeloid leukemia and myelodysplastic syndromes. Cytogenet Genome Res 2007, 118:304-309.
11. Lindvall C., Furge K., Bjorkholm M., Guo X., Haab B., Blennow E., et al. Combined genetic and transcriptional profiling of acute myeloid leukemia with normal and complex karyotypes. Haematologica 2004, 89:1072-1081.
12. Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estey E.H., et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003, 21:4642-4649.
13. Kansal R., Deeb G., Barcos M., Wetzler M., Brecher M.L., Block A.W., et al. Precursor B lymphoblastic leukemia with surface light chain immunoglobulin restriction: a report of 15 patients. Am J Clin Pathol 2004, 121:512-525.
14. Murphy K.M., Levis M., Hafez M.J., Geiger T., Cooper L.C., Smith B.D., et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn 2003, 5:96-102.
15. Nowak N., Snijders A., Conroy J., Alterson D. The BAC resource: tools for array CGH and FISH. Curr Protoc Hum Genet 2005, Chapter 4:Unit 4.13.
16. Snijders A.M., Nowak N., Segraves R., Blackwood S., Brown N., Conroy J., et al. Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet 2001, 29:263-264.
17. Deeb G., Baer M.R., Gaile D.P., Sait S.N., Barcos M., Wetzler M., et al. Genomic profiling of myeloid sarcoma by array comparative genomic hybridization. Genes Chromosomes Cancer 2005, 44:373-383.
18. Gunnarsson R., Isaksson A., Mansouri M., Goransson H., Jansson M., Cahill N., et al. Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients. Leukemia 2010, 24:211-215.
19. Sargent R., Jones D., Abruzzo L.V., Yao H., Bonderover J., Cisneros M., et al. Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia. J Mol Diagn 2009, 11:25-34.
20. van de Wiel M.A., Kim K.I., Vosse S.J., van Wieringen W.N., Wilting S.M., Ylstra B. CGHcall: calling aberrations for array CGH tumor profiles. Bioinformatics 2007, 23:892-894.
21. Baer M.R., Stewart C.C., Dodge R.K., Leget G., Sule N., Mrózek K., et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 2001, 97:3574-3580.
22. Nakano Y., Kiyoi H., Miyawaki S., Asou N., Ohno R., Saito H., et al. Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene. Br J Haematol 1999, 104:659-664.
23. Naoe T., Nakano Y., Kiyoi H. Leukemia relapse reconsidered from the molecular aspect. Leuk Lymphoma 2000, 37:527-534.
24. Stilgenbauer S., Sander S., Bullinger L., Benner A., Leupolt E., Winkler D., et al. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 2007, 92:1242-1245.
25. Ruff P., Saragas E., Poulos M., Weaving A. Patterns of clonal evolution in transformed chronic myelogenous leukemia. Cancer Genet Cytogenet 1995, 81:182-184.
26. Michels E., De Preter K., Van Roy N., Speleman F. Detection of DNA copy number alterations in cancer by array comparative genomic hybridization. Genet Med 2007, 9:574-584.
27. Casas S., Aventin A., Fuentes F., Vallespi T., Granada I., Carrio A., et al. Genetic diagnosis by comparative genomic hybridization in adult de novo acute myelocytic leukemia. Cancer Genet Cytogenet 2004, 153:16-25.
28. Nowak N.J., Miecznikowski J., Moore S.R., Gaile D., Bobadilla D., Smith D.D., et al. Challenges in array comparative genomic hybridization for the analysis of cancer samples. Genet Med 2007, 9:585-595.
29. Cuneo A., Bigoni R., Cavazzini F., Bardi A., Roberti M.G., Agostini P., et al. Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leukemia with normal karyotype. Leukemia 2002, 16:1745-1751.
30. Rowley J.D., Potter D. Chromosomal banding patterns in acute nonlymphocytic leukemia. Blood 1976, 47:705-721.
31. Ogasawara T., Yasuyama M., Kawauchi K. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2). Am J Hematol 2005, 79:136-141.
32. Ratain M.J., Rowley J.D. Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes. Ann Oncol 1992, 3:107-111.
33. Krishnan A., Bhatia S., Slovak M.L., Arber D.A., Niland J.C., Nademanee A., et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000, 95:1588-1593.
34. Arana-Yi C., Block A.W., Sait S.N., Ford L.A., Barcos M., Baer M.R. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: possible role of cytarabine. Leuk Res 2008, 32:1043-1048.
35. Borthakur G., Estey A.E. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome. Curr Oncol Rep 2007, 9:373-377.
36. Seiter K., Feldman E.J., Sreekantaiah C., Pozzuoli M., Weisberger J., Liu D., et al. Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy. Leukemia 2001, 15:963-970.
37. Basecke J., Podleschny M., Becker A., Seiffert E., Schwiers I., Schwiers R., et al. Therapy-associated genetic aberrations in patients treated for non-Hodgkin lymphoma. Br J Haematol 2008, 141:52-59.
38. Wang Y., Zhou R., Liliemark J., Gruber A., Lindemalm S., Albertioni F., et al. In vitro topo II-DNA complex accumulation and cytotoxicity of etoposide in leukaemic cells from patients with acute myelogenous and chronic lymphocytic leukaemia. Leuk Res 2001, 25:133-140.
39. Maciejewski J.P., Mufti G.J. Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood 2008, 112:965-974.
40. Mardis E.R., Ding L., Dooling D.J., Larson D.E., McLellan M.D., Chen K., et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009, 361:1058-1066.
41. Kern W., Schoch C., Haferlach T., Braess J., Unterhalt M., Wormann B., et al. Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities. Leukemia 2000, 14:226-231.
42. Kuptsova N., Kopecky K.J., Godwin J., Anderson J., Hoque A., Willman C.L., et al. Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials. Blood 2007, 109:3936-3944.
43. Staal F., de Ridder D., Szczepanski T., Schonewille T., van der Linden E., van Wering E., et al. Genome-wide expression analysis of paired diagnosis-relapse samples in ALL indicates involvement of pathways related to DNA replication, cell cycle and DNA repair, independent of immune phenotype. Leukemia 2010, 24:491-499.